Former Life Technologies and BD Biosciences Executive John L. “Kip” Miller Joins Solulink’s Board of Directors
News Sep 04, 2013
Solulink, Inc. announced John L. “Kip” Miller has joined the company’s Board of Directors. The addition of Mr. Miller to the Solulink board will be instrumental as the company commences commercialization of its HybriLink™ technology.
The HybriLink technology solves the ‘missing color’ problem: the inability to find the needed antibody labeled with the right fluorophore (color). Often, the desired combination is not commercially available. By providing a simple way to mix and match any fluorophore with any antibody on demand, just‐in‐time at the point‐of‐use, HybriLink dramatically streamlines the development and expansion of multicolor flow panels for flow cytometry research labs. Solulink believes that HybriLink’s ability to offer all antibodies in all fluorophores – including the next generation of emerging fluorophores – resolves a fundamental challenge in flow cytometry and will expand the overall flow cytometry reagents market size.
Mr. Miller brings a solid track record of life science leadership with a strong background in commercial operations, and extensive experience in the life science research and diagnostic markets. Most recently, Mr. Miller served as President of Genetic Systems at Life Technologies. From 2008 to 2011, he served as Senior Vice President of Biodiscovery at Invitrogen Corporation, which merged with Applied Biosystems in 2008 to form Life Technologies. Prior to joining Invitrogen Corporation, Mr. Miller served in various capacities for BD including VP GM of BD Biosciences Research Cell Analysis Business, VP GM of BD Pharmingen and VP Sales and Service the Americas’. Mr. Miller holds a B.S. in Packaging Engineering from Michigan State University.
Currently, Mr. Miller is a co‐founder and member of the Board of Directors at Tonbo Biosciences, and a member of the Board of Directors at Firefly BioWorks.
“We are delighted to welcome Kip to the Solulink board, and excited by the prospect of working with this dynamic leader to advance Solulink’s new HybriLink technology,” said Walt Young, Solulink’s Chairman of the Board. “Kip’s perspective and expertise will be invaluable as Solulink pursues its new HybriLink products for flow cytometry and implements their commercialization strategy.”
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
Shedding Light on How Tumors Become Resistant to ImmunotherapyNews
Researchers have now found that in skin cutaneous melanoma an epigenetic control protein is key to the development of immunotherapy resistance.READ MORE
Comments | 0 ADD COMMENT
Theme: Gathering the Newborn Advances in Cardiology
Mar 19 - Mar 20, 2018